Research and Markets: Hematological Tumor - Pipeline Review, H1 2013

Thu Jul 4, 2013 4:24am EDT

* Reuters is not responsible for the content in this press release.

Research and Markets: Hematological Tumor - Pipeline Review, H1 2013

Research and Markets (http://www.researchandmarkets.com/research/s9bnhb/hematological) has announced the addition of the "Hematological Tumor - Pipeline Review, H1 2013" report to their offering.

Global Markets Direct's, 'Hematological Tumor - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hematological Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hematological Tumor.

Scope

- A snapshot of the global therapeutic scenario for Hematological Tumor.

- A review of the Hematological Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Hematological Tumor pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- News and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hematological Tumor.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Hematological Tumor pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/s9bnhb/hematological

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Photo

After wave of QE, onus shifts to leaders to boost economy

DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.